Press Releases
Keyword Search
 
2016 | 2015 | 2014
DateTitle 
04/27/16Collegium to Host Conference Call to Discuss First Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2016 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (866)864-3220 (U.S.) or (704)908-0478 (International).  An audio webcast will be accessible from the Investor ... 
Printer Friendly Version
04/26/16Collegium Receives FDA Approval for Xtampza™ ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
CANTON, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.   Xtampza ER is Collegium’s first product utilizing its proprietary ... 
Printer Friendly Version
04/08/16Collegium to Present at the 15th Annual Needham Healthcare Conference
CANTON, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company’s CEO, will present at the 15th Annual Needham Healthcare Conference in New York City. The presentation will take place at 1:40 p.m. ET on Wednesday, April 13, 2016 at the Westin Grand Central Hotel. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporat... 
Printer Friendly Version
04/07/16Collegium Announces Publication of Data on the Durability of Pain Relief with Xtampza ER
CANTON, Mass., April 07, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of an analysis of the duration of effect of Xtampza™ ER administered every 12 hours during the Double-blind Maintenance Phase of a multicenter, 12-week clinical study.  The publication is titled, “Evaluation of the Durability of Pain Relief Throughout a 12-Hour Dosing Interval of a Novel, Extended-Release, Abuse-Deterrent Formulation of Oxycodone – Oxycodone DETERx®” a... 
Printer Friendly Version
03/15/16Collegium Reports 2015 Financial Results and Provides Corporate Update
CANTON, Mass., March 15, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its 2015 financial results and provided a corporate update.  “Over the last few months, we made significant progress to advance Xtampza™ ER closer to market launch upon final FDA approval,” stated Michael Heffernan, Collegium’s CEO. “We are very pleased to have recently resolved the Purdue patent litigation that has delayed the potential final approval of Xtampza. As we continue to ... 
Printer Friendly Version
03/10/16Collegium to Host Conference Call to Discuss 2015 Financial Results and Provide Corporate Update
CANTON, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, March 15, 2016 at 7:30 a.m. ET.  The Company will discuss its financial results for 2015 and provide a corporate update.     Conference Call Information:  To access the conference call, please dial (866) 864-3220 (U.S.) or (704) 908-0478 (International).  An audio webcast will be accessible from the In... 
Printer Friendly Version
03/03/16Collegium Announces Publication of Data on the In Vitro Assessment of IV Abuse of Xtampza ER in Journal of Opioid Management
CANTON, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from a laboratory-based extraction, injection and syringeability study for Xtampza® ER compared to other marketed opioid analgesics in peer-reviewed Journal of Opioid Management. The publication is titled, “In Vitro Assessment of the Potential for Abuse via the Intravenous Route of Oxycodone DETERx® Microspheres.” Consistent with FDA’s guidance for develo... 
Printer Friendly Version
02/11/16Collegium Announces Favorable Judgment by the District Court of Massachusetts
CANTON, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the District Court of Massachusetts issued an order for final judgment in favor of Collegium and against plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., and Rhodes Technologies. The judgment relates to Purdue’s three Orange Book-listed patents asserted against Collegium that were the cause of the 30 month stay imposed on our New Drug Application ... 
Printer Friendly Version
02/04/16Collegium Announces Issuance of U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release Technology Platform
Additional Patent Coverage for Lead Product, Xtampza™ ER CANTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,248,195 entitled, "Abuse-deterrent Pharmaceutical Compositions of Opioids and Other Drugs" was issued by the U.S. Patent and Trademark Office (USPTO). The issued patent covers the DETERx technology platform and Collegium's lead product candidate, Xtampza ER (oxycodone) extended-release capsules. The claims... 
Printer Friendly Version
02/02/16Collegium Provides Litigation Update
CANTON, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today provided an update regarding its ongoing litigation with Purdue Pharma L.P. (“Purdue”). On February 1, 2016, the U.S. Court of Appeals for the Federal Circuit rendered its decision to uphold a prior ruling from the U.S. District Court of the Southern District of New York that invalidated four patents associated with OxyContin OP, including Purdue’s three Orange Book-listed patents asserted again... 
Printer Friendly Version
01/25/16Collegium Appoints Ted Schroeder to Board of Directors
CANTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Ted Schroeder to its board of directors. Mr. Schroeder led specialty pharmaceutical company Cadence Pharmaceuticals from its founding until its acquisition by Mallinckrodt Pharmaceuticals for $1.4 billion in 2014. Most recently, Mr. Schroeder co-founded Zavante Therapeutics, which is developing its antibiotic candidate ZTI-01. "Ted has significant experience in th... 
Printer Friendly Version
01/21/16Collegium Announces FDA Acceptance of IND Application for Abuse-Deterrent, Hydrocodone DETERx®
Second Clinical Candidate to Leverage DETERx Technology Platform CANTON, Mass., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application to begin a clinical trial of Hydrocodone DETERx®, an abuse-deterrent, extended-release analgesic for the treatment of chronic pain. This proof of concept clinical trial is intended to evaluate the safety... 
Printer Friendly Version
01/08/16Collegium Pharmaceutical, Inc. Prices Public Offering of $55.0 Million of Common Stock
CANTON, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its public offering of 2,750,000 shares of its common stock at a price to the public of $20.00 per share, before underwriting discounts and commissions. The gross proceeds of this offering are expected to be $55.0 million. All of the shares in this offering are being sold by Collegium.  In addition, Collegium has granted the underwriters a 30-day option to purchase from ... 
Printer Friendly Version